| 杨敬鹏,徐晓楠,王元.我国血液制品企业GMP检查缺陷分析及监管思路探索[J].中国药事,2019,33(6):605-608 |
| 我国血液制品企业GMP检查缺陷分析及监管思路探索 |
| Defect Analysis of GMP Inspection of Blood Product Enterprises and Suggestions on Supervision in China |
| 投稿时间：2019-03-27 |
| DOI：10.16153/j.1002-7777.2019.06.001 |
| 中文关键词: 药品GMP 血液制品生产企业 缺陷 分析 对策 |
| 英文关键词: pharmaceutical GMP blood product enterprise defect analysis countermeasure |
| 基金项目: |
|
| 摘要点击次数: 1281 |
| 全文下载次数: 746 |
| 中文摘要: |
| 目的：为完善我国药品GMP管理，提高企业GMP管理水平提供参考。方法：基于检查37家（次）血液制品生产企业在实施GMP中存在的381项缺陷，采用数据统计的方法进行分类评估，并提出针对性建议。结果与结论：目前，在我国血液制品GMP管理中，存在部分企业实施GMP主动意识不强、企业违反GMP成本较低等问题。建议通过落实企业主体责任、加大检查及处罚力度等办法，减少目前我国血液制品GMP监管中的问题。 |
| 英文摘要: |
| Objective:To provide references for improving pharmaceutical GMP supervision in China and GMP management level of enterprises. Methods:381 defects in the GMP inspection in 37 (times) blood product manufacturers were subject to classified evaluation by statistical methods. Countermeasures were put forward. Results and Conclusion:At present, in the GMP management of blood products in China, there are some problems such as weak initiative awareness of implementing GMP and low cost of violating GMP in some enterprises. It is suggested that the problems in GMP supervision of blood products in China be improued by implementing the main responsibility of enterprises, increasing inspection and punishment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |